University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States13 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT01891318 | |
| Robotic Systems Evaluation for Peripheral Pulmonary Lesions (RISE Trial) | Lung; Node | Not yet recruiting | Not applicable | 2026-09-22 | NCT07735611 | |
| Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Not yet recruiting | Phase 2 | 2026-09-16 | NCT07608718 | |
| Development of MRF for Characterization of Brain Tumors After Radiotherapy | Brain Metastases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Not applicable | 2026-09-15 | NCT06101069 | |
| Patient Navigator PRE-ACT Educational Intervention to Promote Decision Making Among Minorities | Educational Intervention; Minorities | Recruiting | Not applicable | 2026-09-15 | NCT05701085 | |
| Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection | Unintended Weight Loss | Recruiting | Not applicable | 2026-09-15 | NCT05481697 | |
| TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, bile duct cancer, bile duct disorder, bile duct neoplasm, biliary tract disorder, digestive system disorder, digestive system neoplasm, endocrine system disorder, gastric cancer, gastric neoplasm, liver cancer, liver disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, peritoneum cancer, stomach disorder | Not yet recruiting | Not applicable | 2026-08-05 | NCT07653594 | |
| Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Urogenital Diseases, cervix disorder, dysplasia of cervix, female reproductive system disorder, neoplasm, precancerous condition, uterine disorder | Recruiting | Phase 1 | 2026-07-27 | NCT06191133 | |
| Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-05-05 | NCT05400109 | |
| Proton Therapy Patient Registry | neoplasm | Recruiting | Not stated | 2026-04-09 | NCT02986048 | |
| AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-02-27 | NCT03434769 | |
| Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | pancreatic ductal adenocarcinoma | Active, not recruiting | Phase 1 | 2025-09-05 | NCT05209074 | |
| Genomic Analysis of Families With a History of Discordant Cancers | Discordant Cancers | Recruiting | Not stated | 2025-09-03 | NCT04860453 |